RELMADA THERAPEUTICS INC (RLMD)
US75955J4022 - Common Stock
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value...
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance
The DMC did not identify any new safety concerns Relmada to evaluate potential next steps for the REL-1017 program Relmada to continue to focus on the...
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in...
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases of the central...
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company ...
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing...
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc....
Monday 9/16 Insider Buying Report: VSAT, RLMD
Bargain Hunters Take Note: Insider Cluster-Buying At RLMD
Top Buys by Top Brass: Chief Executive Officer Traversa's $395.1K Bet on RLMD
RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q2 2024
RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Relmada Therapeutics (NASDAQ:RLMD) just reported results for the second quarter...
Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases of the central...
Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024
CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024.
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc....
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
7 Penny Biotech Stocks to Triple Your Investment
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.
RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024
RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Relmada Therapeutics (NASDAQ:RLMD) just reported results for the first quarter ...
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023
RLMD stock results show that Relmada Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Relmada Therapeutics (NASDAQ:RLMD) just reported results for the fourth quarter...
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Thursday 2/1 Insider Buying Report: CLF, RLMD